ScreenerHero

RAPP Rapport Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · rapportrx.com
30.86USD-0.93%Mkt Cap: 1.48B $P/E: —

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous sy…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.48B USD
Enterprise Value1.07B USD
Revenue (TTM)20.00M USD
Gross Profit-21.88M USD
Net Income (TTM)-111.48M USD
Revenue/Share0.45 USD
Last Price30.86 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees84
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.12
PEG—
EV/EBITDA-7.00
EV/Revenue53.43
P/S74.73
P/B3.53
EPS (TTM)-2.93
EPS (Forward)-5.09
52W Range
23.7524% of range52.83
52W High52.83 USD
52W Low23.75 USD
Profitability
Gross Margin-109.39%
Oper. Margin-767.58%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.00%
ROA-21.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.47M USD
CapEx (TTM)616.00K USD
FCF Margin-280.08%
FCF Yield-3.78%
Net Debt-425.97M USD
Net Debt/EBITDA2.79
Balance Sheet
Debt/Equity0.02
Current Ratio15.72
Quick Ratio15.35
Book Value/Sh8.82 USD
Cash/Share9.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)63.04 USD
Upside (mean)+104.3%
Target Range50.00 USD – 80.00 USD
50.00+104.3% to mean80.00
# Analysts13
Ownership
Shares Out.47.98M
Float32.39M
Insiders3.90%
Institutions108.93%
Short Interest
Short Ratio8.0d
Short % Float7.42%
Short % Out.4.69%
Shares Short2.25M
Short (prev mo.)2.23M
Technical
SMA 5043.33 (-28.8%)
SMA 20035.79 (-13.8%)
Beta1.22
S&P 52W Chg16.45%
Avg Vol (30d)402.63K
Avg Vol (10d)576.59K
Technical Indicators
RSI (14)23.2
MACD-3.6225
MACD Signal-3.0000
MACD Hist.-0.6225
BB Upper48.88 USD
BB Middle37.63 USD
BB Lower26.38 USD
BB Width59.81%
ATR (14)2.345 USD
Vol Ratio (20d)0.65x